10.6084/m9.figshare.11925636.v1
Craig Leonardi
Craig
Leonardi
Kristian Reich
Kristian
Reich
Peter Foley
Peter
Foley
Hideshi Torii
Hideshi
Torii
Sascha Gerdes
Sascha
Gerdes
Lyn Guenther
Lyn
Guenther
Melinda Gooderham
Melinda
Gooderham
Laura Ferris
Laura
Ferris
Christopher E.M. Griffiths
Christopher E.M.
Griffiths
Hany Elmaraghy
Hany
Elmaraghy
Heidi Crane
Heidi
Crane
Himanshu Patel
Himanshu
Patel
Russel Burge
Russel
Burge
Gaia Gallo
Gaia
Gallo
David Shrom
David
Shrom
Ann Leung
Ann
Leung
Cheng-Yen Lin
Cheng-Yen
Lin
Kim Papp
Kim
Papp
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-To-Severe Psoriasis: Long-Term Results From the UNCOVER-1 and UNCOVER-2 Phase 3 Randomized Controlled Trials
Adis Journals
2020
Ixekizumab
Long-term efficacy
Long-term safety
Maintain
Psoriasis
Quality of life
5 years
2020-03-18 11:24:46
Figure
https://adisjournals.figshare.com/articles/figure/Efficacy_and_Safety_of_Ixekizumab_Through_5_Years_in_Moderate-To-Severe_Psoriasis_Long-Term_Results_From_the_UNCOVER-1_and_UNCOVER-2_Phase_3_Randomized_Controlled_Trials/11925636
<p><strong>Provide enhanced digital features for this article</strong><br></p><p>
This Figshare page contains a Summary Slide. If you are an author of this publication and
would like to provide additional enhanced digital features for your article
then please contact <u>adisrapidplus@springer.com</u>.<br>
<br>
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to
ensure the content is of the highest scientific standard and all features are
marked as ‘peer reviewed’ to ensure readers are aware that the content has been
reviewed to the same level as the articles they are being presented alongside.
Moreover, all sponsorship and disclosure information is included to provide
complete transparency and adherence to good publication practices. This ensures
that however the content is reached the reader has a full understanding of its
origin. No fees are charged for hosting additional open access content.<br>
<br>
Other enhanced features include, but are not limited to:<br>
• Slide decks<br>
• Videos and animations<br>
• Audio abstracts<br>
• Audio slides</p>